# Understanding the Epidemiology of Malaria in Zanzibar Through Molecular and Serological Analysis of Samples Collected During Reactive Case Detection

**Authors:** Varun Goel, Wahida Hassan, Caroline Murphy, Barbara B Choloi, Mohamed Ali, Bakari Mohamed, Abdallah Zacharia, Msolo C Dominick, Kyaw Thwai, Safia Mohammed, Shija J Shija, Jeffrey A Bailey, Anders Björkman, Billy E Ngasala, Eric Rogier, Jonathan J Juliano, Jessica T Lin

PMC · DOI: 10.1093/ofid/ofag051 · Open Forum Infectious Diseases · 2026-02-04

## TL;DR

This study explores the role of non-falciparum malaria species in Zanzibar's recent malaria cases using blood samples and immune responses.

## Contribution

The study reveals the underappreciated role of non-falciparum malaria species in Zanzibar's malaria epidemiology.

## Key findings

- 35.3% of participants had exposure to any malaria species, with Plasmodium falciparum being the most common.
- Travel to mainland Tanzania was a dominant risk factor for seropositivity to all four malaria species.
- Non-falciparum species showed higher seroprevalence in rural districts compared to falciparum.

## Abstract

The Zanzibar archipelago has been a pre-elimination region for malaria thanks to rigorous control interventions, but recent surges in malaria cases have been observed. The contribution of non-falciparum species to the current malaria situation is unknown.

This study investigates the epidemiology of falciparum and non-falciparum malaria species in Zanzibar. Leveraging plasma extracted from dried blood spots (DBS) collected during reactive case detection (RCD) activities across Unguja island from May 2022 to January 2023, we measured immunoglobulin G (IgG) responses to Plasmodium MSP1-19kD antigens using a multiplex bead-based immunoassay. Additionally, active infections were detected using species-specific real-time PCR.

Out of 1618 participants surveyed in 35 RCDs, 35.3% had exposure to any malaria species, with Plasmodium falciparum being the most common (29.8%). Seroprevalences for non-falciparum species were lower: Plasmodium ovale (5.8%), Plasmodium malariae (5.9%), and Plasmodium vivax (5.9%). Active infections were detected in 6.0% of participants, predominantly P. falciparum (4.6%). Travel to mainland Tanzania was a dominant risk factor for seropositivity for all 4 malaria species. Other factors associated with Pf seropositivity (high-risk occupations and female status) were not associated with seropositivity for non-falciparum species. The geographic distribution of non-falciparum exposure differed compared to falciparum, with relatively higher seroprevalences in rural districts, especially Kazkazini A in northern Unguja.

This study suggests a significant contribution of non-falciparum species to the local epidemiology in Zanzibar. Current control and elimination efforts, focused on P. falciparum, may not adequately address exposure to non-falciparum species.

## Linked entities

- **Diseases:** malaria (MONDO:0005136)
- **Species:** Plasmodium falciparum (taxon 5833), Plasmodium ovale (taxon 36330), Plasmodium malariae (taxon 5858), Plasmodium vivax (taxon 5855)

## Full-text entities

- **Genes:** HDGFL2 (HDGF like 2) [NCBI Gene 84717] {aka HDGF-2, HDGF2, HDGFRP2, HRP-2, HRP2}
- **Diseases:** -falciparum infections (MESH:D016778), Plasmodium falciparum parasitemia (OMIM:248310), FMM (MESH:D004195), P. vivax (MESH:D016780), parasitemia (MESH:D018512), Infections (MESH:D007239), RCD (MESH:D000275), Infectious Diseases (MESH:D003141), Malaria (MESH:D008288), P. ovale (MESH:D054092)
- **Chemicals:** artemisinin (MESH:C031327), primaquine (MESH:D011319)
- **Species:** Plasmodium ovale (malaria parasite P. ovale, species) [taxon 36330], Plasmodium malariae (species) [taxon 5858], Pf [taxon 1985359], Plasmodium falciparum (malaria parasite P. falciparum, species) [taxon 5833], Homo sapiens (human, species) [taxon 9606], Plasmodium vivax (malaria parasite P. vivax, species) [taxon 5855]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12911032/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12911032/full.md

## References

31 references — full list in the complete paper: https://tomesphere.com/paper/PMC12911032/full.md

---
Source: https://tomesphere.com/paper/PMC12911032